CoChat

The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial

Open access
Sun, Yi-Yuan, Li, Ming, Li, Yue-Yue, Li, Li-Xiang, Zhai, Wen-Zhe, Wang, Peng, Yang, Xiao-Xiao, Gu, Xiang, Song, Li-Jin, Li, Zhen, Zuo, Xiu-Li, Li, Yan-Qing · 2018 · Scientific Reports

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Irritable bowel syndrome (IBS) is a common disorder in gastrointestinal system and impairs the quality of life of the patients. Clostridium butyricum ( CB ) is a probiotics that has been used in several gastrointestinal diseases. The efficacy of CB in treating IBS is still unknown. This prospective, multi-centre, randomized, double-blind, placebo-controlled trial aimed to assess the efficacy and safety of CB in treating diarrhea-predominant IBS (IBS-D) and analyze the fecal microbiota after treatment. Two hundred patients with IBS-D were recruited and were given CB or placebo for 4 weeks. End points included change from baseline in IBS symptoms, quality of life, stool consistency and frequency. Compared with placebo, CB is effective in improving the overall IBS-D symptoms (−62.12 ± 74.00 vs. −40.74 ± 63.67, P = 0.038) as well as quality of life (7.232 ± 14.06 vs. 3.159 ± 11.73, P = 0.032) and stool frequency (−1.602 ± 1.416 vs. −1.086 ± 1.644, P = 0.035). The responder rates are found higher in CB compared with the placebo (44.76% vs. 30.53%, P = 0.042). The change in fecal microbiota was analyzed and function pathways of CB in treating IBS-D were predicted. In conclusion, CB improves overall symptoms, quality of life and stool frequency in IBS-D patients and is considered to be used as a probiotics in treating IBS-D clinically.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-018-21241-z

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow chart of this study. Reasons for discontinuation are shown.
Figure 1 Flow chart of this study. Reasons for discontinuation are shown.CC BY · PubMed Central
Figure 2 Responder rate after treatment in placebo and Clostridium butyricum (CB) groups. The overall responder rate was higher in the CB group compared with that in the placebo group (P = 0.042). The responder rate of patients with moderate to severe symptoms in the CB group was significantly higher than that in the placebo group (P = 0.007). *P < 0.05, **P < 0.01.
Figure 2 Responder rate after treatment in placebo and Clostridium butyricum (CB) groups. The overall responder rate was higher in the CB group compared with that in the placebo group (P = 0.042). The responder rate of patients with moderate to severe symptoms in the CB group was significantly higher than that in the placebo group (P = 0.007). *P < 0.05, **P < 0.01.CC BY · PubMed Central
Figure 3 The improvement of stool consistency and frequency in placebo and Clostridium butyricum (CB) groups. (a) No significant difference was found in change of Bristol stool scale from baseline to week 4 between the CB group and the placebo group (P = 0.259). (b) The reduction of stool frequency in CB group was significantly superior than that in the placebo group (P = 0.035). *P < 0.05.
Figure 3 The improvement of stool consistency and frequency in placebo and Clostridium butyricum (CB) groups. (a) No significant difference was found in change of Bristol stool scale from baseline to week 4 between the CB group and the placebo group (P = 0.259). (b) The reduction of stool frequency in CB group was significantly superior than that in the placebo group (P = 0.035). *P < 0.05.CC BY · PubMed Central
Figure 4 16 s rRNA pyrosequencing analysis of stool samples. (a) Wilcoxon test of Sob index showed an increased tendency after treating with Clostridium butyricum (CB) (P = 0.063). (b) Heat-map plot with 30 most abundant OTUs in all stool samples. (c) Two clusters were observed using Fisher’s exact test. (d,e) The PCoA plot of placebo and CB groups in baseline and week 4.
Figure 4 16 s rRNA pyrosequencing analysis of stool samples. (a) Wilcoxon test of Sob index showed an increased tendency after treating with Clostridium butyricum (CB) (P = 0.063). (b) Heat-map plot with 30 most abundant OTUs in all stool samples. (c) Two clusters were observed using Fisher’s exact test. (d,e) The PCoA plot of placebo and CB groups in baseline and week 4.CC BY · PubMed Central
Figure 5 Metagenomic analysis of stool samples. (a) ANOSIM analysis of eggNOG between placebo and Clostridium butyricum (CB) groups at baseline and week 4. (b) ANOSIM analysis of KEGG between placebo and CB groups at baseline and week 4. No significant differences were observed between two groups in baseline and week 4 for eggNOG (P = 0.569 in baseline, P = 0.918 in week 4) and KEGG (P = 0.707 in baseline, P = 0.746 in week 4) analysis. (c,d) LEfSe analysis of KEGG pathways between placebo and CB groups at baseline and week 4. (e,f) LDA score of LEfSe analysis at baseline and week 4. (g,h) STAMP analysis of KEGG pathways between placebo and CB groups at baseline and week 4.
Figure 5 Metagenomic analysis of stool samples. (a) ANOSIM analysis of eggNOG between placebo and Clostridium butyricum (CB) groups at baseline and week 4. (b) ANOSIM analysis of KEGG between placebo and CB groups at baseline and week 4. No significant differences were observed between two groups in baseline and week 4 for eggNOG (P = 0.569 in baseline, P = 0.918 in week 4) and KEGG (P = 0.707 in baseline, P = 0.746 in week 4) analysis. (c,d) LEfSe analysis of KEGG pathways between placebo and CB groups at baseline and week 4. (e,f) LDA score of LEfSe analysis at baseline and week 4. (g,h) STAMP analysis of KEGG pathways between placebo and CB groups at baseline and week 4.CC BY · PubMed Central
Figure 6 The whole metabolic pathways of Clostridium butyricum (CB) and placebo via iPath. The blue lines were metabolic pathways dominant in CB group. The red lines were metabolic pathways dominant in placebo group. The green lines were co-pathways in both groups. (a) The metabolic pathways of two groups at baseline. (b) The metabolic pathways of two groups at week 4.
Figure 6 The whole metabolic pathways of Clostridium butyricum (CB) and placebo via iPath. The blue lines were metabolic pathways dominant in CB group. The red lines were metabolic pathways dominant in placebo group. The green lines were co-pathways in both groups. (a) The metabolic pathways of two groups at baseline. (b) The metabolic pathways of two groups at week 4.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 129

Metadata

Authors
Sun, Y.-Y., Li, M., Li, Y.-Y., Li, L.-X., Zhai, W.-Z., Wang, P., Yang, X.-X., Gu, X., Song, L.-J., Li, Z., Zuo, X.-L., & Li, Y.-Q.
Affiliations
Shandong University (CN)
Venue
Scientific Reports
Published
2018-02-14
Volume
8
Issue
1
Pages
2964-2964
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2807514642
Cited by
126
References
40
Citations by year
2026: 11 · 2025: 13 · 2024: 24 · 2023: 16 · 2022: 21 · 2021: 18 · 2020: 14 · 2019: 7 · 2018: 2
FWCI
10.72
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Natural Science Foundation of China (81330012)
  • Natural Science Foundation of Shandong Province (ZR2015H2003)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
Clostridium butyricum, diarrhea-predominant irritable bowel syndrome, probiotics, fecal microbiota, IBS symptoms, quality of life, stool frequency, stool consistency, responder rate
MeSH terms
Fecal Microbiota Transplantation, Adult, Diarrhea, Double-Blind Method, Feces, Female, Humans, Male, Middle Aged, Placebos, Prospective Studies, Quality of Life, Treatment Outcome, Probiotics, Irritable Bowel Syndrome, Clostridium butyricum

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1038/s41598-018-21241-z
The paper
Sun, Y.-Y., Li, M., Li, Y.-Y., Li, L.-X., Zhai, W.-Z., Wang, P., Yang, X.-X., Gu, X., Song, L.-J., Li, Z., Zuo, X.-L., & Li, Y.-Q. (2018). The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Scientific Reports. https://doi.org/10.1038/s41598-018-21241-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.